Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ticketmaster agrees to improve fee transparency amid CMA pressure

(Sharecast News) - Ticketing business Ticketmaster has pledged to improve price transparency following widespread criticism over the cost of tickets to Oasis' reunion tour. The Competition and Markets Authority said Ticketmaster had agreed to tell fans 24 hours in advance if a tiered pricing system would be used and vowed to introduce clearer breakdowns of fees and charges after fans complained about inflated prices and a lack of upfront clarity.

"Fans who spend their hard-earned money to see artists they love deserve to see clear, accurate information, upfront," said CMA chief executive Sarah Cardell. "If Ticketmaster fails to deliver on these changes, we won't hesitate to take further action."

The move comes amid growing scrutiny of ticketing practices across the live entertainment industry, as both regulators and consumer groups in the UK and the US continued to examine competition and consumer protection in the sector.

Ticketmaster promised to roll out changes aimed at "enhancing transparency and trust", including itemised pricing and clearer communication during the purchase process.

Sales of tickets to Oasis' hotly anticipated reunion tour last year saw fans paying hundreds of pounds more than they had expected, with many expressing outrage over allegations that Ticketmaster had used "dynamic pricing" - where ticket prices rise and fall according to demand.

However, the CMA said it had "not found evidence" that such an algorithmic pricing system had been used to adjust the price of Oasis tickets in real time. Oasis even went so far as to claim dynamic pricing had not been used, issuing a statement that they had not agreed to the practice in advance.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.